Optogenetics holds tremendous potential for restoring vision to individuals with late-stage retinal degeneration, particularly those patients who have lost most of their photoreceptors. One promising therapeutic strategy is to express a light-sensitive protein in non-photosensitive bipolar cells by gene therapy. Current approaches are limited by inefficient bipolar targeting and expression, and require application of potentially phototoxic levels of blue-green light to stimulate the optogenetic actuator. The objective of the present proposal is to overcome these challenges by utilizing directed evolution and synthetic biology to engineer an AAV-based delivery system to target red-shifted optogenetic devices to both ON and OFF bipolar cells, and to employ this system to treat blindness in mice.
In Aim 1, we will use directed evolution to engineer new AAV serotypes capable of highly efficient bipolar AAV infection after injection into the vitreous humor.
In Aim 2, we will utilize a novel technolog called CRE-seq to engineer thousands of compact, ON bipolar-specific promoters that exhibit excellent specificity and a wide range of expression strengths. In addition, we will engineer an AAV-deliverable synthetic gene circuit to target an optogenetic inhibitor specifically to OFF bipolar cells.
In Aim 3, we will combine the tools developed in Aims 1 and 2 with the use of red-shifted optogenetic devices to restore functional vision to rd1 mutant mice. We recently discovered the enzyme responsible for the 'rhodopsin- porphyropsin' switch in vertebrates, and we will use this enzyme to red-shift optogenetic devices, making them sensitive to far red light (> 650 nm). This therapeutic approach has the potential to dramatically improve light- sensitivity in the rescued mice and will avoid the retinal damage associated with high-intensity blue light exposure, thereby permitting unprecedented levels of functional restoration and setting the stage for future trials in human patients.
Photoreceptor degeneration represents a major cause of blindness. In this proposal, we will develop an innovative strategy for treating blindness by converting bipolar cells in the retina into light sensors that can detect far red light. This approach will avoid problems associated with the use of optogenetic vision restoration devices that are sensitive to potentially phototoxic short wavelength light, and will set the stage for futre trials in human patients with blindness.
|Shen, Susan Q; Myers, Connie A; Hughes, Andrew E O et al. (2016) Massively parallel cis-regulatory analysis in the mammalian central nervous system. Genome Res 26:238-55|
|Kramlinger, Valerie M; Nagy, Leslie D; Fujiwara, Rina et al. (2016) Human cytochrome P450 27C1 catalyzes 3,4-desaturation of retinoids. FEBS Lett 590:1304-12|
|Lopes, Ricardo J; Johnson, James D; Toomey, Matthew B et al. (2016) Genetic Basis for Red Coloration in Birds. Curr Biol 26:1427-34|
|Toomey, Matthew B; Lind, Olle; Frederiksen, Rikard et al. (2016) Complementary shifts in photoreceptor spectral tuning unlock the full adaptive potential of ultraviolet vision in birds. Elife 5:|
|Rosa, Juliana M; Bos, RÃ©mi; Sack, Georgeann S et al. (2015) Neuron-glia signaling in developing retina mediated by neurotransmitter spillover. Elife 4:|
|Toomey, Matthew B; Collins, Aaron M; Frederiksen, Rikard et al. (2015) A complex carotenoid palette tunes avian colour vision. J R Soc Interface 12:20150563|
|Gaub, Benjamin M; Berry, Michael H; Holt, Amy E et al. (2015) Optogenetic Vision Restoration Using Rhodopsin for Enhanced Sensitivity. Mol Ther 23:1562-71|
|Enright, Jennifer M; Toomey, Matthew B; Sato, Shin-ya et al. (2015) Cyp27c1 Red-Shifts the Spectral Sensitivity of Photoreceptors by Converting Vitamin A1 into A2. Curr Biol 25:3048-57|